Added to Saved items
This page has been archived. It has not been updated since 21/09/2015. External links and references may no longer work.
This article is for Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.

Read COVID-19 guidance from NICE

Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.

See also separate Glucose-6-phosphate Dehydrogenase Deficiency article.

Favism describes the susceptibility to, and clinical presentation of, acute haemolytic crises as a consequence of eating broad beans in a subgroup of patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.

It can be potentially life-threatening. Broad beans are derived from the plant Vicia fava - hence, the condition's name. Susceptible patients may also experience the syndrome when exposed to the plant's pollen.

G6PD is crucial in maintaining red cell homeostasis and its deficiency leads to increased susceptibility to haemolysis induced by drugs, infections and substances in food. There is a huge number of polymorphisms of the gene with variable effects on the activity of the enzyme and a wide range of phenotypic susceptibility to haemolysis.

The gene for G6PD is located on the X chromosome. It is therefore an X-linked inherited disease that primarily affects men. It can have clinical effects in homozygous women and a proportion of female heterozygous carriers.

It is thought that the susceptibility to favism is determined by a combination of the particular G6PD polymorphism and other factors, such as genetics and also metabolism of the active ingredients in the beans, which causes oxidative damage in red blood cells. An infectious agent such as a virus may also play a role in the development of favism.[1]

  • G6PD deficiency is the most common enzymopathy of man of clinical significance. It affects more than 400 million people worldwide.[2]
  • Patients with favism are always G6PD-deficient but not all G6PD-deficient individuals develop haemolysis when they ingest fava beans.
  • The vast majority of cases of favism occur in individuals with severely deficient variants of G6PD.
  • Favism is more common in males than in females.[3]
  • There may be a past history of episodes of neonatal or childhood jaundice.
  • A dietary history may reveal recent ingestion of broad beans.
  • Check for recent medication changes or history consistent with infection.

Favism leads to acute, massive intravascular haemolysis. Its main clinical features are:

  • Acute back and/or abdominal pain.
  • Acute pallor due to anaemia.
  • Haemoglobinuria causing the passage of dark or orangey-yellow urine.
  • Jaundice.
  • Patients with G6PD deficiency are prone to gallstones and splenomegaly due to recurrent, often subclinical, episodes of haemolysis.
  • Dipstick urine testing to reveal evidence of haemoglobinuria.
  • FBC will show acute haemolytic anaemia picture with low haemoglobin.
  • Reticulocyte count may be elevated (although often normal in the early acute phase).
  • Raised indirect bilirubin (unconjugated) indicating haemolysis.
  • LFTs are usually normal.
  • Serum lactate dehydrogenase may be elevated, indicating haemolysis.
  • Serum haptoglobins may be low, indicating haemolysis.
  • Abdominal ultrasound may be used to detect gallstones and/or splenomegaly.
  • Coombs' test is negative.
  • G6PD activity assay in undiagnosed cases - may be normal if there is significant reticulocytosis, as reticulocytes are rich in the enzyme; assay may need to be repeated in the convalescent phase.
  • Avoid further ingestion of broad beans.
  • Folic acid supplementation.
  • Iron supplementation if there is ongoing acute severe intravascular haemolysis.
  • Oxygen therapy.
  • Bed rest and transfer to a high care/intensive care setting.
  • Intravenous fluids to reduce the chance of acute oliguric renal impairment.
  • Blood transfusion or exchange transfusion is sometimes needed to treat severe anaemia.
  • Death due to acute severe haemolytic anaemia (relatively rare).
  • Ophthalmological damage due to intraocular intravascular haemolysis.
  • Acute kidney injury.
  • Susceptibility to infection.

This is variable depending on the degree of susceptibility to favism, quantity of beans ingested and access to acute medical care. Most cases do well with supportive care but there is significant morbidity and some mortality associated with the disease.

  • Avoidance of ingestion of broad beans in patients known to have G6PD deficiency, or who have suffered previous episodes of favism.
  • However, one study found that the majority of patients who ate fava beans after an attack had no symptoms.[1].
  • Genetic counselling and screening may be useful where there is a family history of G6PD deficiency, to allow diagnosis before exposure to haemolytic precipitants.
  • Population screening and health education programmes in areas of high prevalence of G6PD deficiency have been shown to reduce the incidence of favism in the at-risk population.[4]
  • See separate article on G6PD deficiency for a list of medications to be avoided in G6PD-deficient patients.

Are you protected against flu?

See if you are eligible for a free NHS flu jab today.

Check now

Further reading and references

  1. Ahmed SN; Do favic patients resume fava beans ingestion later in their life, a study for this, and a new hypothesis for favism etiology. Hematol Oncol Stem Cell Ther. 2013 Mar6(1):9-13. doi: 10.1016/j.hemonc.2013.03.002. Epub 2013 Mar 22.

  2. Osman HG, Zahran FM, El-Sokkary AM, et al; Identification of Mediterranean mutation in Egyptian favism patients. Eur Rev Med Pharmacol Sci. 2014 Oct18(19):2821-7.

  3. Osman HG, Zahran FM, El-Sokkary AM, et al; Oxidative stress and antioxidant defense in Egyptian favism patients. Eur Rev Med Pharmacol Sci. 2013 May17(9):1211-7.

  4. Verma IC, Puri RD; Global burden of genetic disease and the role of genetic screening. Semin Fetal Neonatal Med. 2015 Aug 3. pii: S1744-165X(15)00078-5. doi: 10.1016/j.siny.2015.07.002.

newnav-downnewnav-up